 |
 |
source: Viartis 3rd May 2009 - New research PRAMIPEXOLE CLINICAL TRIAL RESULTS Pramipexole (known under the trade names Mirapexin®, Sifrol®, Mirapex® and Pexola®) is a drug that is used for Parkinson's Disease, on its own or with L-dopa. However, there are numerous possible side effects. It is claimed that the outcome of a new study on Pramipexole is set to change the treatment of depressive symptoms in Parkinson's Disease because Pramipexole is claimed to relieve the depressive symptoms of Parkinson's Disease. However, the results show that the effect of Pramipexole was little better than the effect of a placebo : depression (reduced by -5.9 v -4.0), geriatric depression (improved by 2.5 v 1.7), Parkinson's Disease symptoms (reduced by -4.4 v -2), daily living (improved by -2.4 v -1.2). Those taking only a placebo improved on all the scales as well, thereby greatly reducing the actual benefit of Pramipexole. The placebo achieved a similar without the widespread side effects of Pramipexole. For more information go to the News release. Previous research by the same author also showed that Pramipexole was not not much more effective for Parkinson's Disease depression than a placebo. For more information go to the Complete abstract. In order to refer to this article on its own click here. Rayilyn Brown Director AZNPF Arizona Chapter National Parkinson Foundation [log in to unmask] ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn